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Summary
Background The cross-sectional HIV care continuum is widely used to assess the success of HIV care programmes 
among populations of people with HIV and the potential for ongoing transmission. We aimed to investigate whether 
a longitudinal continuum, which incorporates loss to follow-up and mortality, might provide further insights about 
the performance of care programmes.
Methods In this longitudinal cohort study, we included individuals who entered the UK Collaborative HIV Cohort 
(CHIC) study between Jan 1, 2000, and Dec 31, 2004, and were linked to the national HIV cohort database (HIV and 
AIDS Reporting System). For each month during a 10 year follow up period, we classified individuals into one of ten 
distinct categories according to engagement in care, antiretroviral therapy (ART) use, viral suppression, loss to cohort 
follow-up and loss to care, and mortality, and assessed the proportion of person-months of follow-up spent in each 
stage of the continuum. 5 year longitudinal continuums were also constructed for three separate cohorts (baseline 
years of entry 2000–03, 2004–07, and 2008–09) to compare changes over time.
Findings We included 12 811 people contributing 1 537 320 person-months in our analysis. During 10 years of 
follow-up, individuals spent 811 057 (52·8%) of 1 537 320 person-months on ART. Of the 811 057 person-months spent 
on ART, individuals had a viral load of 200 copies per mL or less for 607 185 (74·9%) person-months. 10 years after 
cohort entry, 3612 (28·1%) of 12 811 individuals were lost to follow-up, 954 (26·4%) of whom had transferred to a 
non-CHIC UK clinic for care. By 10 years, 759 (5·9%) of 12 811 participants who entered the cohort had died. Loss to 
follow-up decreased and the proportion of person-months that individuals spent virally suppressed increased over 
calendar time.
Interpretation Loss to follow-up in HIV care programmes was high and rates of viral suppression were lower than 
previously reported. Complementary information provided by a longitudinal continuum might highlight areas for 
intervention along the HIV care pathway, however, transfers outside the cohort must be accounted for.
Funding Medical Research Council, UK.
Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
For both the individual and population-wide benefits of 
antiretroviral therapy (ART) to be realised, people with HIV 
need to be diagnosed promptly, to engage with HIV care, 
and to initiate and to adhere to lifelong therapy. The HIV 
continuum of care has become a widely used approach to 
describe the benchmark stages along the HIV care 
pathway to viral suppression. The cross-sectional design of 
a traditional continuum of care enables up-to-date 
information about the proportion of people with HIV at 
each stage of the care pathway to be presented for a specific 
population at a particular timepoint in one comprehensible 
figure. Thus, the continuum is useful for monitoring public 
health and comparing the performance of HIV care 
programmes, which is particularly relevant in view of public 
health goals to minimise ongoing transmission and 
the UNAIDS 90-90-90 target.1 However, a longitudinal 
continuum of care might provide further insights into 
understanding the success of HIV care programmes. A 
longitudinal framework has the potential to estimate the 
time taken for a population to progress from one stage of 
the continuum to the next, which is an important distinction 
considering that late HIV diganosis and late ART intitiation 
have been shown to have a negative effect on rates 
of transmission and clinical outcomes.2–6 An individual’s 
position in the later stages of the continuum might change 
over time due to loss of virological suppression, treatment 
interruptions, or disengagement from care. These trans-
itions are not evident in a typical cross-sectional continuum. 
Furthermore, many individuals with HIV are not accounted 
for; losses along the care continuum are not well 
characterised and only individuals who are alive at the time 
of assessment are included, which is likely to overestimate 
the spectrum of engagement in care.
The 90-90-90 UNAIDS continuum is under review with 
suggested expansion to include a so-called fourth 90, 
which takes into account quality of life.7 Other alternative 
methods of describing a continuum of care include 
the consideration of a so-called states and transitions 
framework that additionally describes the rate of transition 
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both forward and backward between stages of the 
continuum,8 time-to-event analyses of the stages of 
the continuum using longitudinal cohort data,9 and the 
incorporation of mortality as an outcome along the HIV 
care pathway.10,11 However, stages along the continuum are 
usually considered to be fixed and are assumed not to vary 
with time. Although Nosyk and colleagues12 used a 
combination of fixed stages and stages that could change 
over time to present a series of cross-sectional care 
continuums over time, mortality was not included.
Therefore, the aim of this study was to develop a 
method to outline the progression of a population of 
individuals diagnosed with HIV through the stages of 
the HIV care pathway during a 10 year period, 
incorporating the outcomes of loss to cohort follow-up 
and loss to care and mortality.
Methods
Study design and participants
In this longitudinal cohort study, we included 
individuals who entered the UK Collaborative HIV 
Cohort (CHIC) study13 between Jan 1, 2000, and 
Dec 31, 2004, to allow for a maximum of 10 years of 
follow-up, ending no later than Dec 31, 2014. The UK 
CHIC study is an ongoing cohort of HIV-positive 
individuals (aged >16 years) who have accessed care at 
21 HIV clinics in the UK at any time from 1996 onwards, 
which is linked to the national HIV surveillance cohort 
based in Public Health England (the HIV and AIDS 
Reporting System [HARS]). Indi viduals who were not 
linked to the HARS were excluded from our analyses, to 
ensure we could reliably estimate transfer and true loss 
to care for all individuals.14 Mortality data in the UK 
CHIC Study are reported by participating centres and 
supplemented through linkage to the HARS, which is 
linked to the Office for National Statistics mortality 
registry.6,14
We also estimated 5 year continuums, allowing 
individuals who entered the cohort between Jan 1, 2005, 
and Dec 31, 2009, to be additionally included.
The UK CHIC Study was approved by the West 
Midlands multicentre research ethics committee and 
local ethics committees, and does not require informed 
consent.
Procedures
Data was provided electronically by each participating 
centre annually. Baseline was the date of entry into the 
Research in context
Evidence before this study
We searched PubMed for titles and abstracts of literature 
published in English between Jan 1, 2011, and Dec 31, 2017, using 
the search terms “continuum of care”, “care continuum”, “cascade 
of care”, and “care cascade”. Search results were reviewed to 
identify publications describing longitudinal or cohort care 
continuums. National surveillance reports for the UK were also 
reviewed to obtain current estimates of the continuum of care in 
the UK. The continuum of care in the UK in 2015, estimated that 
83% of individuals with HIV were receiving antiretroviral therapy 
(ART) and 79% were virologically suppressed. Cross-sectional 
continuums of care have certain limitations because they do not 
incorporate patient outcomes or engagement fully, which is 
crucial for measuring the success of HIV care, and thus methods 
of presenting a longitudinal HIV continuum of care are starting to 
be explored. Such cohort continuums might have only a short 
period of follow-up after HIV diagnosis, and thus only include 
newly diagnosed individuals. Two studies have additionally 
incorporated mortality endpoints in the care continuum. One of 
the studies used cumulative incidence estimates from 
time-to-event analyses to describe the mean time taken to 
progress through stages of care. Another study reported the 
proportion of individuals with optimal, suboptimal, and poor 
outcomes, including loss to follow-up and death, up to 
12 months after enrolment. A states and transitions framework 
has been theorised, which would describe rates of transition 
between the stages of HIV care, and the proportion of people at 
each stage. However, to date, an entire pathway has not been 
estimated in any setting because extensive data would be 
required. Although these methods have both advantages and 
disadvantages, no single method for estimating a longitudinal 
continuum of care has been recommended.
Added value of this study
We have used comprehensive clinical data from a large 
observational dataset, linked to national cohort and mortality 
data, to devise a longitudinal measure of the continuum of HIV 
care. This method uses time-updated factors to account for 
changes in viral suppression and engagement in care with time, 
and incorporates loss to care and mortality data, presenting 
population-level data in a single comprehensible figure. Our 
study reports the proportion of person-months individuals 
with HIV spent in suboptimum care categories during a 10 year 
follow-up period. We found that individuals spent 5% of 
person-months ART-naive with a CD4 count of 350 cells per µL 
or less and 25% of person-months on ART with a detectable 
viral load. Furthermore, 28% of individuals were lost to 
follow-up 10 years after entry, with a quarter of this loss to 
follow-up explained by transfer of care.
Implications of all the available evidence
A longitudinal continuum of care provides additional insights 
regarding the success of HIV care programmes for a particular 
setting, and identifies areas for improvement. Data on 
cumulative loss to follow-up provides insights into the potential 
number of people not receiving HIV care, which, if out-migration 
is low, could contribute substantially to the ongoing epidemic. 
Early interventions to improve engagement in care are a priority 
for achieving an optimal continuum of care.
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study with a follow-up end date that was 10 years after 
cohort entry, regardless of death or loss to follow-up. For 
each month during the 10 year follow-up period, we 
classified individuals into one of ten categories on the 
basis of current engagement in care, ART use, viral 
suppression, loss to follow-up, and death to assess the 
proportion of person-months of follow-up spent in each 
stage of the care continuum (appendix p 1). We defined 
engagement in care on a monthly basis using the 
REACH algorithm.15 Months of follow-up were classified 
as in care if an individual was adhering to a predicted 
visit schedule, and not in care if an individual was not 
compliant with a predicted visit schedule. ART use was 
defined once an individual was reported to have started 
any antiretroviral drugs. Individuals were considered to 
have viral suppression if they had a viral load of 200 copies 
per mL or less, recorded in the previous 9 months. Since 
individuals stable on ART at the time of this study would 
be expected to have assessment of viral load every 
6 months according to the British HIV Association 
monitoring guidelines, a 9 month period was chosen to 
allow some flexibility around the expected timeframe for 
viral load measurements.16 If no viral load was recorded 
in this period, the viral load was assumed to be detectable.
British HIV Association standards of care recommend 
all individuals with HIV attend a HIV clinic for care at 
least once in 12 months, thus loss to follow-up was 
defined when an individual was classified as not in care 
for at least 9 consecutive months.17 Therefore, 
individuals predicted to return for treatment within 
2 months of an observed visit who were lost to follow-up 
would not have attended for care for at least 11 months, 
and individuals predicted to return within 6 months 
would not have attended for at least 15 months. We 
further classified person-months lost to follow-up as 
transfer if individuals were lost to follow-up but had a 
HARS record of attendance at a non-CHIC centre for 
that year. Person-months were classified as true loss to 
care if individuals were lost to follow-up with no HARS 
record of attendance at a non-CHIC clinic. Once an 
individual had died, they were categorised as such for all 
remaining months.
To compare changes across calendar years, we reduced 
the period of follow-up to 5 years, and estimated the care 
continuum for three separate cohorts according to year 
of entry: 2000–03 (to end of 2008), 2004–07 (to end of 2011), 
2008–09 (to end of 2014). These periods were selected to 
correspond with changes in HIV treatment guidelines 
for initiation of ART in 2008.
Statistical analysis
We generated and summarised the longitudinal 
continuum categories and generated stacked area charts 
using SAS software (version 9.4; SAS Institute, Cary, 
NC, USA). We estimated the proportion of all person-
months of follow-up spent in each state over the 
duration of the continuum as the number of 
person-months categorised to each state, divided by the 
total months of person follow-up in the longitudinal 
continuum. Cross-sectional assessments at any 
timepoint relative to cohort entry (eg, 12, 24, 36 months) 
were the number of person-months in that continuum 
state at that time, divided by the total number of person-
months included at that time (also equal to the number 
of people included in the continuum for all timepoints). 
We also did sensitivity analyses to test the definition of 
loss to cohort follow-up and investigated the inclusion 
of treatment interruption in the care continuum 
categories (appendix pp 4, 5).
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
A total of 13 762 individuals were entered into the UK CHIC 
study between 2000, and 2004, of whom 12 811 (93·1%) were 
linked to a HARS record. Thus 12 811 individuals with HIV, 
contributing 1 537 320 person-months, were included in 
our analyses. Individuals who were linked to a HARS 
record were more likely to be men (p<0·0001) and to have 
acquired HIV through sex between men or through sex 
between men and women (p<0·0001) than individuals who 
were not linked (table). Individuals who were not linked to 
a HARS record were more likely to have missing data on 
ethnicity (179 [18·8%] of 951 individuals vs 423 [3·3%] of 
12 811 individuals) and route of HIV acquisition 
(256 [26·9%] of 951 individuals vs 871 [6·8%] of 
12 811 individuals) than individuals linked to a HARS 
record (p<0·0001). A higher proportion of individuals not 
linked to a HARS record were lost to follow-up 10 years 
after cohort entry than individuals linked to a HARS record 
(453 [47·6%] of 951 individuals vs 3613 [28·2%] of 
12 811 individuals).
The mean age at study entry for the 10-year cohort was 
34 years (SD 9·2). Ethnicity was balanced across the 
included cohort (table). The proportion of individuals 
older than 50 years, and the number of individuals with 
CD4 counts higher than 350 cells per µL at baseline 
increased over time (table).
The 10 year longitudinal continuum of care included a 
total 1 537   320 person-months of follow-up (figure 1), of 
which individuals spent 811 057 (52·8%) person-months on 
ART. Overall, individuals had viral loads of 200 copies per 
mL or less for 607 185 (39·5%) of 1 537 320 person-months, 
which accounted for 607 185 (74·9%) of 811 057 person-
months spent on ART. Of 1 098 190 person-months spent 
alive and retained in the cohort, individuals were ART-
experienced for 811 057 (73·9%) person-months and were 
virologically suppressed for 607 185 (55·3%) person-
months.
See Online for appendix
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A total of 287 133 person-months were spent ART-
naive, of which 130 114 (45·3%) were spent engaged in 
care with a CD4 count higher than 350 cells per µL, 
82 102 (28·6%) person-months were spent engaged in 
care with a CD4 count of 350 cells per µL or less, and 
74 917 (26·1%) person-months were categorised as not in 
care. Of 82 102 person-months spent ART-naive with a 
CD4 count of 350 cells per µL or less, only 10 674 (13·0%) 
of these person-months corresponded to the 3 months 
following HIV diagnosis. The number of person-months 
spent engaged in care was higher for participants who 
had initiated ART than participants who were ART-naive, 
with 115 048 (14·2%) of 811 057 person-months spent 
ART-experienced classified as not in care, compared with 
74 917 (26·1%) of 287 133 person-months spent ART-
naive. A total of 379 819 (24·7%) of 1 537 320 person-
months were classified as lost to follow-up, of which 
86 771 (22·8%) of 379 819 person-months were categorised 
as transfer to another HIV clinic for care. Thus, 
293 048 (19·1%) of 1 537 320 person-months represented 
true loss to care (figure 1). In total, 759 (5·9%) of 
12 811 individuals had died within 10 years of cohort 
entry, representing 59 311 (3·9%) of 1 537 320 person-
months lost due to death (figure 1).
The number of individuals receiving ART increased 
with time from entry (3304 [25·8%] of 12 811 individuals 
at entry vs 7676 (59·9%) of 12 811 individuals 10 years after 
entry; appendix p 2). However, 764 (6·0%) of 
12 811 individuals were retained, but had not received 
ART 10 years after entry into care. 1036 (31·4%) of 3304 of 
individuals who were receiving ART at entry had a viral 
load of 200 copies per mL or less (8·0% of all individuals), 
and 6029 (78·5%) of 7676 individuals who had received 
ART and were in follow-up at 10 years had a viral load 
of 200 copies per mL or less. Thus, 6029 (47·0%) of 
12 811 individuals in the cohort had a viral load of 
200 copies per mL or less 10 years after cohort entry. The 
proportion of individuals lost to follow-up increased 
rapidly in the 2 years after entry, and 10 years after cohort 
entry, 3612 (28·1%) of 12 811 individuals were lost to 
follow-up, of whom 954 (26·4%) had transferred to a non-
CHIC UK clinic for care (appendix p 2). The number of 
patients classified as true loss to care remained constant 
across the cohort between 2 years and 10 years after entry 















<30 283 (29·8%) 4004 (31·3%) 3182 (32·0%) 3344 (29·7%) 1414 (26·6%)
30–39 409 (43·0%) 5698 (44·5%) 4458 (44·8%) 4669 (41·5%) 2030 (38·2%)
40–49 165 (17·4%) 2239 (17·5%) 1650 (16·6%) 2379 (21·1%) 1324 (24·9%)
≥50 82 (8·6%) 870 (6·8%) 664 (6·7%) 867 (7·7%) 550 (10·3%)
Sex
Men 567 (59·6%) 8396 (65·5%) 6565 (66·0%) 7416 (65·9%) 3686 (69·3%)
Women 373 (39·2%) 4415 (34·5%) 3389 (34·0%) 3843 (34·1%) 1632 (30·7%)
Ethnicity
White 344 (36·2%) 5646 (44·1%) 4399 (44·2%) 5106 (45·4%) 2543 (47·8%)
Black 341 (35·9%) 5660 (44·2%) 4334 (43·5%) 4914 (43·6%) 2087 (39·2%)
Other or unknown 266 (28·0%) 1505 (11·7%) 1221 (12·3%) 1239 (11·0%) 688 (12·9%)
Mode of HIV acquisition
Sex between men 257 (27·0%) 5157 (40·3%) 4054 (40·7%) 4617 (41·0%) 2205 (41·5%)
Heterosexual 396 (41·6%) 6343 (49·5%) 4873 (49·0%) 5477 (48·6%) 2355 (44·3%)
Other or unknown 298 (31·3%) 1311 (10·2%) 1027 (10·3%) 1165 (10·3%) 758 (14·3%)
Newly diagnosed 723 (76·0%) 9888 (77·2%) 7948 (79·8%) 8110 (72·0%) 3737 (70·3%)
CD4 count (cells per µL)
<200 142 (14·9%) 2838 (22·2%) 2226 (22·4%) 2582 (22·9%) 1115 (21·0%)
201–350 83 (8·7%) 1998 (15·6%) 1463 (14·7%) 2101 (18·7%) 1057 (19·9%)
>350 199 (20·9%) 3414 (26·6%) 2509 (25·2%) 3833 (34·0%) 2081 (39·1%)
Data not available 527 (55·4%) 4561 (35·6%) 3756 (37·7%) 2743 (24·4%) 1065 (20·0%)












Data are n (%), or median (IQR). CHIC=Collaborative HIV Cohort. HARS=HIV and AIDS Reporting System.
Table: Characteristics of individuals enrolled in the UK CHIC study by year of cohort entry
Figure 1: 10 year longitudinal continuum of care
Person-months for each stage of the continuum: ART–/EIC/CD4 >350, 130 114 
person-months; ART–/EIC/CD4 ≤350, 82  102 person-months; ART–/NIC, 74 917 
person-months; ART+/EIC/VL >200, 116 599 person-months; ART+/EIC/VL 
≤200, 579 410 person-months; ART+/NIC/VL ≤200, 27 775 person-months; 
ART+/NIC/VL >200, 87 273 person-months; true LTC, 293 048 person-months; 
transfer, 86 771 person-months; and dead, 59 311 person-months. See appendix 
(p 1) for a full description of each stage of the continuum.LTC=loss to care. 
ART+=antiretroviral therapy experienced. ART–=antiretroviral therapy naive. 
NIC=not in care. EIC=engaged in care. VL=viral load. ART–=antiretroviral 
therapy naive. 





































Time from cohort entry (months)
Dead (3·9%)
ART+/NIC/VL >200 copies per mL 
ART+/NIC/VL ≤200 copies per mL 
ART+/EIC/VL ≤200 copies per mL 
ART+/EIC/VL >200 copies per mL 
ART-experienced (52·8%)
ART–/NIC 
ART–/EIC/CD4 ≤350 cells per mL




Lost to follow-up (24·7%)
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(2650 [20·7%) of 12 811 individuals vs 2568 [20·7%] of 
12 811 individuals), whereas loss to follow-up due to 
transfer increased between 2 years and 10 years after 
entry (556 [4·3%] vs 954 [7·4%]; appendix p 2). As a 
proportion of all individuals lost to cohort follow-up, 
transfer increased from 17·2% (556 of 3206 individuals) 
at 2 years after cohort entry to 26·4% (954 of 
3612 individuals) at 10 years after cohort entry 
(appendix p 2).
We included 9954 individuals (contributing 
597 240 person-months) in the 2000–03 cohort, 
11 259 indi viduals (contributing 675 540 person-months) 
in the 2004–07 cohort, and 5318 individuals (contributing 
319 080 person-months) in the 2008–09 cohort. True loss 
to care was lower in the cohort that entered the study in 
2008–09 than the 2000–03 cohort (figure 2). Of 
the 5318 individuals included in the 2008–09 cohort, 
732 (13·8%) individuals were defined as true loss to 
care 2 years after entry, and 865 (16·3%) individuals at 
5 years after entry (appendix p 3). Comparison of the 
9954 individuals included in the 2000–03 cohort revealed 
that 2 years after entry, 2190 (22·0%) individuals were 
defined as true loss to care, and 2295 (23·1%) of 
individuals 5 years after entry. The number of participants 
not in care before ART initiation was also lower in the 
year after cohort entry in the 2008–09 cohort than the 
2000–03 cohort (689 [13·0%] of 5318 individuals vs 
2307 [23·2%] of 9954 individuals; appendix p 3).
Participants in the 2008–09 cohort spent a lower 
proportion of person-months before ART initiation 
engaged in care with a CD4 count of 350 cells per µL or less 
than did participants in the 2000–03 and 2004–07 cohorts 
(figure 2). In the 2008–09 cohort, 13 210 (17·8%) of 
74 076 person-months before ART initiation were spent 
engaged in care with a CD4 count of 350 cells per µL or less, 
compared with 51 350 (30·0%) of 171 031 person-months in 
the 2000–03 cohort, and 44 498 (24·2%) of 183 942 person-
months in the 2004–07 cohort. ART initiation seemed to be 
more rapid in the most recent cohort than the earlier 
cohorts; 3036 (57·1%) of 5318 individuals had started ART 
1 year after entry in the 2008–09 cohort compared with 
4446 (44·7%) of 9954 individuals in the 2000–03 cohort and 
5662 (50·3%) of 11 259 individuals in the 2004–07 cohort 
(appendix p 3). The proportion of person-months on ART 
spent with viral suppression over a 5 year period also 
increased over time: 188 550 (68·0%) of 277 148 person-
months in the 2000–03 cohort, 272 006 (75·3%) of 
361 082 person-months in the 2004–07 cohort, and 
148 340 (78·0%) of 190 280 person-months in the 
2008–09 cohort (figure 2). Mortality seemed to be 
moderately lower in the 2008–09 cohort than the 
2000–03 cohort (figure 2).
Sensitivity analyses showed that the length of time 
used to define loss to follow-up did not change the rate of 
loss to follow-up substantially, and inclusion of treatment 
interruption in the care continuum did not alter our 
findings substantially (appendix pp 4,5).
Figure 2: 5 year longitudinal 
care continuum by calendar 
year of cohort entry
Person-months for each stage 
of the continuum: 
ART–/EIC/CD4 >350, 70 576 
(2000–03), 93 695 (2004–07), 
and 42 573 (2008–09) 
person-months; ART–/EIC/CD4 
≤350, 51 350 (2000–03), 
44 498 (2004–07), 13 210 
(2008–09) person-months; 
ART–/NIC, 49 105 (2000–03), 
45 749 (2004–07), 18 293 
(2008–09) person-months; 
ART+/EIC/VL >200, 54 154 
(2000–03), 51 058 (2004–07), 
22 545 (2008–09) 
person-months; ART+/EIC/VL 
≤200, 179 775 (2000–03), 
259 598 (2004–07), 140 887 
(2008–09) person-months; 
ART+/NIC/VL ≤200, 
8775 (2000–03), 12 408 
(2004–07), 7453 (2008–09) 
person-months; ART+/NIC/VL 
>200, 34 444 (2000–03), 
38 018 (2004–07), 19 395 
(2008–09) person-months; 
true LTC, 107 733 (2000–03), 
87 975 (2004–07), 37 805 
(2008–09) person-months; 
transfer, 24 724 (2000–03), 
27 032 (2004–07), 10 713 
(2008–09) person-months; 
dead, 16 604 (2000–03), 
15 509 (2004–07), 6206 
(2008–09) person-months. 
See appendix (p 1) for a full 
description of each stage of 




naive. NIC=not in care. 
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Discussion
We observed an increasing probability of ART use and 
subsequent viral suppression with time from entry into 
HIV care in this longitudinal continuum of care. However, 
10 years after study entry, 6·0% of individuals were alive 
and accessing care (ie, not lost to follow-up), but had not 
started ART, 12·9% were accessing care and had initiated 
ART, but had not achieved viral suppression, and 
20·7% were lost to care.
We present a novel method of describing population-
level progress through the stages of the care pathway 
within the HIV continuum of care. By establishing 
categories to represent stages along the care continuum, 
and suboptimum responses along the care pathway, all 
individuals who enter care are accounted for. Following a 
closed population for a fixed number of years enabled us 
to incorporate loss to follow-up and mortality data, 
providing additional insights into the traditional 
continuum of care. We used time-updated measures of 
the stages of the care pathway if possible, allowing 
individuals to move between stages while maintaining a 
population-based overview.
In this study, participants spent 74·9% of person-
months on ART with a viral load below 200 copies 
per mL. This result indicates worse virological outcomes 
among people living with HIV than that of a traditional 
cross-sectional continuum of care in the UK, which 
reports viral suppression rates of 94% in people given 
ART.18 Although these estimates are not directly 
comparable, they highlight the different conclusions that 
might be drawn from a cross-sectional versus longitudinal 
continuum of care.9,19 The proportion of person-months 
spent with an unsuppressed viral load has implications 
for both ongoing transmission and individual outcomes, 
and is therefore a useful measure of programmatic 
success. The context in which this non-suppression 
occurs is also important; if viral suppression is not 
achieved or lost due to poor adherence during periods of 
high-risk behaviours, this is of particular concern in view 
of the potential for onward transmission.
Loss to care was higher in this longitudinal continuum 
of care than that previously reported using cross-sectional 
measures. National surveillance data estimate that 
95% of individuals who attend HIV clinics for care in a 
calendar year will return for care the following year.20 The 
increasing cumulative rate of loss to care in this study is 
consistent with previous reports that one in five people 
who attend for care in the UK will be lost to follow-up 
within 5 years,21,22 and suggests that a substantial group of 
patients disengage from care for periods of time and are 
slow to, or never, re-engage. Most individuals who were 
lost to follow-up in this study were lost to follow-up 
within 2 years of entry to care, suggesting that 
interventions to improve engagement soon after 
diagnosis are needed. A previous study23 in the UK found 
newly diagnosed individuals, women, younger adults, 
black African individuals, and individuals who have 
acquired HIV outside of the UK are most likely 
to be lost to follow-up. In our analysis only around a 
quarter of loss to follow-up was explained by transfer of 
care elsewhere, with the remainder unaccounted for. 
Some of this loss to care might be explained by migration; 
in the UK, approximately a quarter of individuals who do 
not return for care and who can be traced are thought to 
have left the country, but most people cannot be 
accounted for.20,23 Therefore, for most individuals lost to 
care who remain in the country, but do not access care, 
this might have important consequences for individual 
and public health, since individuals who are disengaged 
from care are more likely to transmit HIV to others and 
to have poor health outcomes themselves, possibly only 
re-engaging with care when they become ill.2,3 This 
underscores the importance of ensuring that all people 
with HIV have access to HIV treatment, free at the point 
of use and, although we have no information on the 
migration status of individuals lost to care, such access 
needs to include documented and undocumented 
migrants, which is the standard procedure in the UK.
Changes were observed in the longitudinal continuum 
of care over time. Fewer person-months were spent naive 
to ART with CD4 counts of 350 cells per µL or less, ART 
initiation was more rapid, more individuals achieved 
viral suppression, and fewer individuals were lost over 
time. These differences are likely to reflect changes in 
treatment guidelines and developing knowledge about 
the benefits of ART initiation at high CD4 cell counts 
during this time period.24 Thus, although ART initiation 
was less rapid in the earlier cohorts than the later cohorts, 
this might simply reflect adherence to treatment 
guidelines at the time. Earlier ART initiation in the 
cohort who entered the study between 2008, and 2009, 
might contribute to the lower number of person-months 
categorised as lost to follow-up over time. A lower 
proportion of person-months after ART initiation were 
classified as not in care than before ART initiation, 
consistent with other studies, albeit in different health-
care settings.25–27 Whether accumulation of follow-up data 
in the setting of immediate initiation of ART will result 
in lower overall loss to care should be monitored.
This approach is similar to that of McNairy and 
colleagues,19 who categorised the outcomes of all 
individuals who entered care into poor, suboptimal, or 
optimal responses at several points during the first year 
of ART. The long follow-up of the present study, and 
more detailed categorisation of the stages of the care 
pathway, provides further insights about the long-term 
experience of HIV care in the UK. In our analysis, we 
include time-updated measures of both viral suppression 
and engagement in care that are more reflective of real-
life scenarios in which individuals can both disengage 
from and re-engage with care and rebound and suppress 
their viral load. The use of the large clinical cohort from 
the UK CHIC Study, which represents more than half of 
all people diagnosed with HIV in the UK, and the 
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availability of a national cohort to which it can be linked, 
is a strength of this study. This linkage allows us to 
reliably account for transfer of care and assess true loss 
to care rates and mortality. Smaller clinical cohorts not 
linked to national HIV care data might generate inflated 
estimates of loss to follow-up, particularly if people 
frequently transfer care between HIV clinics.
Our study has limitations. Our study followed up a 
closed cohort over a long period of time, thus our 
findings might be less generalisable to more recent 
cohorts with different demographic and social 
characteristics and for whom treatment guidelines have 
changed. We have included a selected population of 
individuals linked to care rather than a newly diagnosed 
population, and of those, only individuals who could be 
linked to a HARS record. In the UK, 97% of newly 
diagnosed individuals link to care within 3 months. This 
rate of linkage is similar across age, sex, ethnicity, and 
HIV risk subgroups, which would indicate that the 
population who link to care are largely representative of 
the whole diagnosed population.28 In the present study, 
individuals linked to a HARS record were more likely to 
have available data on ethnicity and route of HIV 
acquisition, and were less likely to be lost to follow-up 
than individuals not linked to HARS. These differences 
could indicate that individuals who could not be linked to 
a HARS record are less likely to be engaged in care or are 
more likely to transfer between HIV care centres than 
individuals linked to HARS, which could result in some 
bias in our estimated rates of transfer and loss to care. 
Because our study investigated a cohort linked to HIV 
care, we have not measured all stages of the continuum 
of care. This method could not be easily applied to the 
first stage of the continuum (ie, to estimate person-time 
spent undiagnosed) since reliable dates of HIV 
acquisition are rarely known. The absence of data on out-
migration presents a challenge in truly understanding 
how much of this loss to care is explained by people who 
remain in the country without accessing care.
Although a cross-sectional continuum of care is a useful 
tool for assessing the potential public health impact of 
programmatic performance, additional insights can be 
gained from a longitudinal approach. Understanding 
patterns and determinants of both disengagement and 
re-engagement with care and the role of migration is 
important for improving retention of individuals within 
the HIV care pathway in the UK.
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